The partnership unites RAD's products with AtomVie's capabilities in the manufacture and distribution of radiopharmaceuticals.

An antibody-drug conjugate ... with another $1.525 billion in success-based milestones. It is playing catch-up with another B7-H3 ADC candidate from MSD and Daiichi Sankyo, ifinatamab deruxtecan ...

AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new ... trials led by B7-H4- and Claudin18.2-targeting ...

Rapid Novor has published a study that highlights the power of combining de novo antibody protein sequencing with ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained ...

Recent advances in the management of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, have shown that inhibiting the interaction between the α4β7 integrin and the ...

Myasthenia gravis (MG) is an antibody-mediated chronic neuromuscular disorder leading to fluctuating weakness and early muscle fatigue, with limited treatment options available. In MG, such as other ...

ASX-listed Radiopharm Theranostics has joined forces with a renowned global radiopharmaceutical manufacturer to produce its cancer-fighting treatment that targets commonly over-expressed protein in ...

The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly specific manner. Understanding the antibody response to influenza neuraminidase (NA ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

To keep up to date with the latest Number 1s each week, sign up to our newsletter. Unsubscribe at any time.